NCT06139406

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) \[Part A: Dose Escalation\] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs \[Part B: Dose Expansion\].

Conditions

• Lymphoma, Non-Hodgkin

Interventions

Type	Name	Description
DRUG	JNJ-87801493	JNJ-87801493 will be administered subcutaneously.
DRUG	JNJ-80948543	JNJ-80948543 will be administered subcutaneously.
DRUG	JNJ-75348780	JNJ-75348780 will be administered subcutaneously.

Timeline

• Start date: 2023-12-06
• Primary completion: 2026-01-30
• Completion: 2026-08-31
• First posted: 2023-11-18
• Last updated: 2026-04-13

Locations

12 sites across 4 countries: Australia, Denmark, Israel, Spain

Regulatory

• FDA-regulated drug study